Search
OpenAI Eyes Share in Profits from Clients' AI-Driven R&D Successes
2026-01-23 /
Read about 0 minute
Author：小编
On January 23, as reported by The Information, during the Davos Forum, OpenAI's CFO, Sarah Friar, mentioned that in the realm of pharmaceutical R&D, OpenAI could potentially secure licenses for drugs developed with the aid of its technology. Furthermore, the company stands to gain a portion of the financial returns generated by clients who harness AI technology in their endeavors. Nevertheless, Friar refrained from elaborating on the specific ways in which OpenAI would support companies in the discovery of novel drugs, adhering to the common business practice of keeping strategic details confidential until formal agreements are in place.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
